1. Infliximab Treatment of Refractory Cardiac Sarcoidosis.
- Author
-
Asawaeer M, Widener B, Singhal V, DeVries MJ, Romberger DJ, Erickson AR, and Chatzizisis YS
- Abstract
Treatment of cardiac sarcoidosis is challenging, as the disease can be refractory to traditional treatment with steroids. Infliximab, a tumor necrosis factor-α inhibitor, has been reportedly used in cardiac sarcoidosis, but published evidence is limited. The potential cardiotoxicity of infliximab and the Food and Drug Administration black-box warning for patients with heart failure have hindered the use of this agent in cardiac sarcoidosis. Here, we report a case of refractory cardiac sarcoidosis successfully treated with infliximab and discuss the important role of fluorine-18-fluorodeoxyglucose positron emission tomography in prognostication and guidance of therapy. ( Level of Difficulty: Intermediate. )., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF